{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-110088","form_type":"8-K","ticker":"RLMD","cik":"0001553643","company_name":"RELMADA THERAPEUTICS, INC.","filed_at":"2025-11-13T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.721678+00:00","generated_at":"2026-05-16T20:20:57.340985+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Relmada reports NDV-01 92% CR rate; FDA alignment for Phase 3; closes $100M financing","bullets":["NDV-01 9-month data: 92% complete response (CR) at any time in NMIBC; 91% in BCG-unresponsive subgroup; no Grade 3 TRAEs.","FDA aligned on two Phase 3 registrational paths for NDV-01 in high-risk BCG-unresponsive and intermediate-risk NMIBC; trials start H1 2026.","Closed $100M underwritten offering of stock and pre-funded warrants on Nov 5; net ~$94M; cash runway extended into 2028.","Q3 2025 net loss $10.1M ($0.30 per share) vs $21.7M ($0.72) in Q3 2024; R&D expense fell to $4.0M from $11.1M.","Appointed Dr. Max Kates to Clinical Advisory Board; Sepranolone Phase 2 in Prader-Willi syndrome expected H1 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-110088","json":"https://secwatch.observer/filing/0001213900-25-110088.json","markdown":"https://secwatch.observer/filing/0001213900-25-110088.md","text":"https://secwatch.observer/filing/0001213900-25-110088.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1553643/000121390025110088/0001213900-25-110088-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1553643/000121390025110088/ea026563001-8k_relmada.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T20:20:57.340985+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}